Last updated: 20 May 2024 at 4:20pm EST

Phillip Sharp Net Worth




The estimated Net Worth of Phillip A Sharp is at least $30.3 Million dollars as of 29 February 2024. Phillip Sharp owns over 30,000 units of Alnylam Pharmaceuticals Inc stock worth over $7,857,300 and over the last 21 years he sold ALNY stock worth over $21,935,627. In addition, he makes $495,707 as Independent Director at Alnylam Pharmaceuticals Inc.

Phillip Sharp ALNY stock SEC Form 4 insiders trading

Phillip has made over 19 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of ALNY stock worth $1,777,500 on 29 February 2024.

The largest trade he's ever made was selling 294,100 units of Alnylam Pharmaceuticals Inc stock on 14 May 2004 worth over $17,281,316. On average, Phillip trades about 11,038 units every 93 days since 2003. As of 29 February 2024 he still owns at least 30,000 units of Alnylam Pharmaceuticals Inc stock.

You can see the complete history of Phillip Sharp stock trades at the bottom of the page.





Phillip Sharp biography

Dr. Phillip A. Sharp Ph.D. is Independent Director of Alnylam Pharmaceuticals, Inc. Dr. Sharp is a scientific founder of Alnylam and has served as a member of our board of directors since June 2002. Dr. Sharp is an Institute Professor at the David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), and was the Founding Director of the McGovern Institute for Brain Research at MIT. Dr. Sharp has been a professor at MIT since 1974. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Sharp also serves as a director of Syros Pharmaceuticals, Inc. and formerly served as a director of Biogen Inc., which he co-founded in 1978.

What is the salary of Phillip Sharp?

As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of Phillip Sharp at Alnylam Pharmaceuticals Inc is $495,707. There are 13 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.



How old is Phillip Sharp?

Phillip Sharp is 75, he's been the Independent Director of Alnylam Pharmaceuticals Inc since 2002. There are no older and 20 younger executives at Alnylam Pharmaceuticals Inc.

What's Phillip Sharp's mailing address?

Phillip's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.



What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.



What does Alnylam Pharmaceuticals Inc's logo look like?

Alnylam Pharmaceuticals Inc logo

Complete history of Phillip Sharp stock trades at Alnylam Pharmaceuticals Inc, Biogen Inc, Syros Pharmaceuticals, and Vir Biotechnology Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
29 Feb 2024 Phillip A Sharp
Director
Option 30,000 $59.25 $1,777,500
29 Feb 2024
30,000
15 Aug 2022 Phillip A Sharp
Director
Option 33,670 $33.77 $1,137,036
15 Aug 2022
33,670
9 Feb 2022 Phillip A Sharp
Director
Option 30,000 $11.33 $339,900
9 Feb 2022
30,000
25 Nov 2020 Phillip A Sharp
Director
Option 30,000 $9.30 $279,000
25 Nov 2020
265,633
12 Feb 2020 Phillip A Sharp
Director
Option 30,000 $12.48 $374,400
12 Feb 2020
265,633
18 Nov 2019 Phillip A Sharp
Director
Option 15,000 $16.43 $246,450
18 Nov 2019
250,633
15 Apr 2019 Phillip A Sharp
Director
Option 15,000 $22.09 $331,350
15 Apr 2019
250,633
13 Mar 2018 Phillip A Sharp
Director
Option 15,000 $21.35 $320,250
13 Mar 2018
155,795
9 Mar 2018 Phillip A Sharp
Director
Option 15,000 $27.28 $409,200
9 Mar 2018
155,795
1 Feb 2017 Phillip A Sharp
Director
Option 25,000 $31.29 $782,250
1 Feb 2017
165,795
25 Jan 2017 Phillip A Sharp
Director
Option 15,000 $31.39 $470,850
25 Jan 2017
155,795
18 Jan 2017 Phillip A Sharp
Director
Option 15,000 $15.91 $238,650
18 Jan 2017
155,795
4 Dec 2015 Phillip A Sharp
Director
Option 30,000 $14.28 $428,400
4 Dec 2015
170,795
13 Oct 2014 Phillip A Sharp
Director
Option 110,000 $7.71 $848,100
13 Oct 2014
184,996
22 Jan 2013 Phillip A Sharp
Director
Buy 4,967 $20.13 $99,986
22 Jan 2013
14,269
21 Feb 2012 Phillip A Sharp
Director
Buy 9,302 $10.75 $99,997
21 Feb 2012
9,302
14 May 2004 Phillip A Sharp
Director
Sale 294,100 $58.76 $17,281,316
14 May 2004
478,000
13 May 2004 Phillip A Sharp
Director
Option 65,000 $11.73 $762,450
13 May 2004
65,000
4 May 2004 Phillip A Sharp
Director
Sale 78,900 $58.99 $4,654,311
4 May 2004
772,100


Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: